Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 EUR | -.--% | -.--% | +3.73% |
22/04 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
11/04 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Business Summary
Number of employees: 1,071
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Payroll and Financial Management, Software, Consulting, and Personnel and International Services
100.0
%
| 53 | 100.0 % | 76 | 100.0 % | +43.78% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Finland
100.0
%
| 53 | 100.0 % | 76 | 100.0 % | +43.78% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 01/05/01 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 01/23/01 |
Director/Board Member | 54 | 01/94/01 | |
Mari Kankaanpää
HRO | Human Resources Officer | 47 | 01/22/01 |
Susanna Suomela
SAM | Sales & Marketing | 43 | 01/23/01 |
Sari Kivi
PRN | Corporate Officer/Principal | - | - |
Emil Hermansson
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 16/21/16 |
Chairman | 58 | 01/18/01 | |
Director/Board Member | 56 | 01/22/01 | |
Director/Board Member | 54 | 01/94/01 | |
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 01/05/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,354,144 | 14,354,144 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.73% | 38.44M | |
-2.36% | 6.59B | |
-.--% | 62.2M | |
-17.65% | 59.44M | |
-30.30% | 55.56M |
- Stock Market
- Equities
- ADMIN Stock
- Company Administer Oyj